Wall Street Analysts Believe Paysign (PAYS) Could Rally 65.76%: Here's is How to Trade
The mean of analysts' price targets for Paysign (PAYS) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Business Services Stocks Lagging Paysign (PAYS) This Year?
Here is how Paysign, Inc. (PAYS) and Rollins (ROL) have performed compared to their sector so far this year.
Does Paysign (PAYS) Have the Potential to Rally 74% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 74% in Paysign (PAYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Paysign (PAYS) a New Buy Stock
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Paysign, Inc. (PAYS) Q3 2025 Earnings Call Transcript
Paysign, Inc. ( PAYS ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Mark Newcomer - Co-Founder, President & CEO Jeffery Baker - CFO & Treasurer Matthew Turner - President of Patient Affordability Conference Call Participants Jacob Stephan - Lake Street Capital Markets, LLC, Research Division Gary Prestopino - Barrington Research Associates, Inc., Research Division Peter Heckmann - D.A. Davidson & Co., Research Division Presentation Operator Good afternoon.
Paysign: Gaining Traction In The Patient Affordability Space Into 2026 (Hold)
Paysign posted strong Q2 2025 results, with 33% YoY revenue growth and robust Pharma segment momentum, driven by US tariffs and new client wins. PAYS is rated a hold, as the stock trades at fair value ($5.83), despite expected high demand for co-payment cards and expanded patient affordability programs. Pharma segment revenue surged 189% YoY, offsetting a 4.7% YoY decline in the core Plasma segment, which faces ongoing headwinds from transitioning centers.
Paysign, Inc. (PAYS) Q2 2025 Earnings Call Transcript
Paysign, Inc. (NASDAQ:PAYS ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Jeffery B. Baker - CFO & Treasurer Mark R.
Finding the Best Cheap Stocks to Buy Now
Investors who want to keep buying stocks in July and throughout the second half of 2025 might consider adding exposure to highly-ranked cheap stocks that trade for $10 a share or less.
Paysign (PAYS) is on the Move, Here's Why the Trend Could be Sustainable
Paysign (PAYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Paysign: Growth In Payments Met With High Valuation
Paysign has achieved strong double-digit revenue growth year-over-year and expanded its market share significantly. The company now controls about 50% of the plasma donation center market after adding 132 new centers. Paysign maintains a healthy balance sheet and expects to improve its bottom-line financials.
Recent Price Trend in Paysign (PAYS) is Your Friend, Here's Why
Paysign (PAYS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Predict a 44.4% Upside in Paysign (PAYS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Paysign (PAYS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
